Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Astellas Says It Aims for ‘Friendly’ Bid of CV Therapeutics As Q3 Profits Decline

This article was originally published in PharmAsia News

Executive Summary

TOKYO - An Astellas Pharma senior executive said during a Feb. 2 earnings call the company is aiming to make its bid for CV Therapeutics a friendly proposal rather than a hostile takeover

You may also be interested in...

Astellas Looks To Increase U.S. Presence With Bid For CV Therapeutics

In a surprise move spurred by a desire to own a greater share of the promising angina drug Ranexa, Astellas announced Jan. 27 its hostile offer for partner CV Therapeutics in a cash deal worth roughly $1 billion

Astellas Expansion Of Domestic Sales Impressive Despite NHI Pricing; Launches Mycamine in U.K.

TOKYO - Astellas' Japanese domestic sales expanded 4.5 percent compared to last year, which analysts said were impressive because of the lowering of the National Health Insurance pricing across the board in April. The company attributed the increase to sales of long-acting angiotensin-II receptor antagonist Micardis (telmisartan), the hypnotic Myslee, and a few other products

Astellas Announces 32 Percent Increase In Earnings; Anticipates 10.4 Percent Drop With Prograf Patent Expiry In FY '08

TOKYO - Astellas posted May 13 fiscal 2007 net revenue of ¥177.4 billion ($1.7 billion), a 32 percent increase over the ¥131.3 billion ($1.3 billion) posted the previous fiscal year. For the present fiscal year however, the Tokyo-based company, which focuses in urology, immunology and inflammatory, diabetes, CNS/pain, infectious diseases and cancer, forecasts a 10.4 percent drop in net revenue to ¥159 billion ($1.518 billion). In a May 14 earnings call with investors and analysts, company president and CEO Masafumi Nogimori noted sales of immunosuppressant Prograf (tacrolimus) grew in each region, with global sales of ¥203 billion. However, the drug's substance patent expired in April. "Based on this, U.S. sales will decline by 5.5 percent," Nogimori said

Related Content




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts